ONCT Insider Trading Activity and SEC Form 4 Filings
ONCT insider trading summary
No open-market insider purchases or sales of Oncternal Therapeutics, Inc. (ONCT) have been reported on SEC Form 4 in the past 12 months.
Latest ONCT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Apr 8, 2024 | Robert James Wills | Director | Buy | $28K (3,086 @ $8.96) |
| Mar 28, 2024 | Robert James Wills | Director | Buy | $59K (6,914 @ $8.48) |
| Feb 23, 2024 | David F Hale | Director | Buy | $2K (266 @ $9.04) |
| Feb 23, 2024 | David F Hale | Director | Buy | $6K (714 @ $9.04) |
| Feb 23, 2024 | Robert James Wills | Director | Sell | $9K (980 @ $9.04) |
| Jun 14, 2023 | Gunnar F. Kaufmann | Chief Scientific Officer | Buy | $1K (3,000 @ $0.36) |
| Jun 12, 2023 | Gunnar F. Kaufmann | Chief Scientific Officer | Buy | $9K (25,000 @ $0.35) |
| Apr 14, 2023 | James B Breitmeyer | Chief Executive Officer | Buy | $14K (47,750 @ $0.30) |
| Apr 14, 2023 | James B Breitmeyer | Chief Executive Officer | Buy | $653 (2,250 @ $0.29) |
| Apr 14, 2023 | Salim Yazji | Chief Medical Officer | Buy | $2K (5,000 @ $0.30) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.